25.17% -0.185

Avenue Therapeutics Inc (ATXI)

概要ニュース株価時系列 Financials なぜATXIが下落しているのか？ディスカッション予測株式分割

Relative Volume:

ネットキャッシュフロー:

Avenue Therapeutics Inc Stock (ATXI) Company Profile

Avenue Therapeutics Inc

Healthcare (1116)

Biotechnology (622)

ATXI's Discussions on Twitter

Compare ATXI vs VRTX, REGN, ARGX, ALNY, ONC

株式	価格	時価総額	収益	当期純利益	現金流量	EPS
ATXI Avenue Therapeutics Inc	0.55	0	1.40M	-2.95M	-1.83M	-0.9554
VRTX Vertex Pharmaceuticals Inc	441.20	112.22B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	750.57	79.35B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	849.04	52.80B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	309.66	41.32B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	323.87	35.95B	5.36B	287.73M	924.18M	2.5229

Avenue Therapeutics Inc (ATXI) 最新ニュース

Avenue Therapeutics Inc (ATXI) 財務データ

Avenue Therapeutics Inc (ATXI)

Avenue Therapeutics Inc Stock (ATXI) Company Profile

Compare ATXI vs VRTX, REGN, ARGX, ALNY, ONC

Avenue Therapeutics Inc (ATXI) 最新ニュース

Visa Inc. $V is Douglas Lane & Associates LLC’s 10th Largest Position - Defense World

Form 10-KAnnual report [Section 13 and 15(d), not S-K Item 405] - ADVFN

Stock List: Research Stocks from Around the World - GuruFocus

Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights - The Manila Times

Fortress Biotech (NASDAQ: FBIO) turns 2025 profit with $205M PRV sale and new royalties - Stock Titan

フォートレス・バイオテック、2025年度財務実績及び直近の企業ハイライトを報告 - Moomoo

Avenue Therapeutics Focuses on Neurologic Disease Therapies with ATX-04 and IV Tramadol as Key Product Candidates in 2026 - Minichart

ATXI: 2025 net loss narrowed to $2.9M as focus shifts to ATX-04 and IV tramadol amid funding challenges - TradingView

Avenue Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

Avenue Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com

Maze Therapeutics (NASDAQ:MAZE) Upgraded by Wall Street Zen to Hold Rating - MarketBeat

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million - The Manila Times

Turn Therapeutics secures up to $25M in financing from Avenue Capital Group - MSN

Turn Therapeutics Secures Up to $25 Million Financing from Avenue Capital to Advance Atopic Dermatitis and Onychomycosis Programs - Minichart

Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group - PharmiWeb.com

Turn Therapeutics Secures Up To $25 Million Term Loan Facility From Avenue Venture Opportunities - TradingView — Track All Markets

Turn Therapeutics (Nasdaq: TTRX) secures up to $25M loan facility - Stock Titan

Turn Therapeutics Inc. Enters into Loan and Security Agreement for Up to $25 Million Growth Capital Loan Facility with Avenue Venture Opportunities Fund Ii, L.P - marketscreener.com

Turn Therapeutics secures $25M loan facility from Avenue Capital - Investing.com

Turn Therapeutics, Inc. Secures Up to $25 Million in Financing from Avenue Capital Group - marketscreener.com

Turn Therapeutics Inc. announced that it expects to receive $25 million in funding from Avenue Capital Management II, L.P. - MarketScreener

Fortress Biotech (FBIO) Executive Vice Chairman granted 475,424 restricted shares - Stock Titan

ATXI SEC FilingsAvenue Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Neurology stocks rebound in 2025 after midyear slump - BioWorld MedTech

TG Therapeutics, Inc.Common Stock (NQ: TGTX - The Chronicle-Journal

Tangible book value per share of Avenue Therapeutics, Inc. – LS:A40BWJ - TradingView

Net current asset value per share of Avenue Therapeutics, Inc. – LS:A40BWJ - TradingView

Intellia Therapeutics (NASDAQ:NTLA) Upgraded at Wall Street Zen - MarketBeat

Deal Watch: Esperion Augments Cardiovascular Franchise Via Corstasis Buyout - Citeline News & Insights

Halozyme Therapeutics, Inc. $HALO Shares Sold by Cary Street Partners Financial LLC - MarketBeat

Edgewise Therapeutics (NASDAQ:EWTX) Downgraded to Sell Rating by Wall Street Zen - MarketBeat

ATXI Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

PKTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Avenue Therapeutics to develop add-on Pompe disease treatment - Pompe Disease News

Palvella Therapeutics Announces Proposed Public Offering - GlobeNewswire

Avenue Therapeutics licenses ATX-04 for Pompe disease treatment By Investing.com - Investing.com Australia

Avenue Therapeutics Licenses ATX-04 for Pompe Disease - TipRanks

Avenue Therapeutics (OTC: ATXI) licenses ATX-04 Pompe therapy from Duke - Stock Titan

Avenue Therapeutics licenses ATX-04 for Pompe disease treatment - Investing.com

After Menkes drug approval, Fortress moves to cash in $205M voucher - Stock Titan

Avenue Therapeutics Enters into Exclusive Worldwide License - GlobeNewswire

Lion Street Advisors LLC Buys 5,619 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat

Halozyme Therapeutics (NASDAQ:HALO) Downgraded to Hold Rating by Wall Street Zen - MarketBeat

Candel Therapeutics Announces Pricing of Public Offering - The Manila Times

Ikarian Capital discloses 4.1% Avenue Therapeutics (ATXI) stake in 13G/A - Stock Titan

Context Therapeutics (NASDAQ:CNTX) Upgraded to Hold at Wall Street Zen - MarketBeat

Contineum Therapeutics (NASDAQ:CTNM) Rating Increased to Hold at Wall Street Zen - MarketBeat

Wall Street Zen Downgrades Kyverna Therapeutics (NASDAQ:KYTX) to Sell - MarketBeat

Warrant approval could dilute Dogwood Therapeutics (NASDAQ: DWTX) holders - Stock Titan

Anchor Line Partners, LLC and Northwood Investors, LLC secures 98,500 s/f lease Stoke Therapeutics at 245 Fifth Ave. - NEREJ

Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion - WSJ

Avenue Therapeutics Inc (ATXI) 財務データ

収益

当期純利益

現金流量

EPS

ATXIに似た銘柄